Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 14/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14675766 | 0.87 | L3MBTL1 (0.57) | KAT6AL3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL5899488 | 0.84 | KAT6A (0.49) | KAT6AL3MBTL1ALDH1A1GAA | |
| SCHEMBL7948519 | 0.83 | L3MBTL1 (0.55) | KAT6AL3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL1771100 | 0.82 | MMP1 (0.56) | KAT6AL3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL5899419 | 0.81 | ALDH1A1 (0.49) | L3MBTL1ALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL5899417 | 0.81 | ADAMTS4 (0.50) | KAT6AGAA | |
| SCHEMBL5899700 | 0.81 | HTT (0.44) | ALDH1A1LMNAGAA | |
| SCHEMBL5899418 | 0.81 | PFKFB3 (0.54) | KAT6ALMNASMN1; SMN2 | |
| SCHEMBL5899456 | 0.81 | MMP2 (0.59) | KAT6AALDH1A1 | |
| SCHEMBL5899495 | 0.80 | ALDH1A1 (0.50) | ALDH1A1LMNASLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025445-A1 | 11-Beta HSD1 inhibitors | WYETH | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025445-A1 | 11-Beta HSD1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | KAT6A 2440/4885L3MBTL1 1816/4885ALDH1A1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.